Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

I, Stevic; V, Müller; K, Weber; PA, Fasching; T, Karn; F, Marmé; C, Schem; E, Stickeler; C, Denkert; Mackelenbergh M, van; C, Salat; A, Schneeweiss; K, Pantel; S, Loibl; M, Untch; H, Schwarzenbach

doi:10.1186/s12916-018-1163-y

Public

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Published in BMC medicine • Oct 10, 2018

Authors:

Stevic I

Müller V

Weber K

Abstract

<h4>Background</h4>The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).<h4>Methods</h4>First, miRNA expression profiles we...

View

Open Access

Subject

Breast cancer

Her2-positive

Neoadjuvant Therapy

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!